Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George Awad

Showing results (1-10 of 57) with videos related to

Pageof 6
Sort By:
Evidence-Based Mental Health|April 28, 2006
First episode psychosis: olanzapine and haloperidol provide similar improvements in quality of life and social functioningGeorge Awad
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|June 17, 2004
Second-generation antipsychotics: looking beyond efficacyA George Awad
Journal of Psychopharmacology (Oxford, England)|December 16, 2011
Is it time to consider comorbid substance abuse as a new indication for antipsychotic drug development?A George Awad
Journal of Psychiatry & Neuroscience : JPN|May 16, 2006
The rational use of medications in acute psychotic presentations -- the case for less is moreA George Awad
Expert Review of Pharmacoeconomics & Outcomes Research|August 21, 2015
'The patient': at the center of patient-reported outcomesA George Awad
Expert Review of Pharmacoeconomics & Outcomes Research|October 1, 2011
Quality-of-life assessment in schizophrenia: the unfulfilled promiseA George Awad
CNS Drugs|December 5, 2018
Revisiting the Concept of Subjective Tolerability to Antipsychotic Medications in Schizophrenia and its Clinical and Research Implications: 30 Years LaterA George Awad
Expert Review of Pharmacoeconomics & Outcomes Research|February 4, 2010
Subjective tolerability of antipsychotic medications and the emerging science of subjective tolerability disordersA George Awad
Acta Psychiatrica Scandinavica. Supplementum|May 10, 2005
Neuroleptic dysphoria 50 years laterA George Awad, Dieter Naber
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|June 17, 2004
Is neuroleptic dysphoria a variant of drug-induced extrapyramidal side effects?Lakshmi P Voruganti, A George Awad
Pageof 6

Showing results (1-10 of 57) with videos related to

Sort By:
Pageof 6
Evidence-Based Mental Health|April 28, 2006
First episode psychosis: olanzapine and haloperidol provide similar improvements in quality of life and social functioningGeorge Awad
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|June 17, 2004
Second-generation antipsychotics: looking beyond efficacyA George Awad
Journal of Psychopharmacology (Oxford, England)|December 16, 2011
Is it time to consider comorbid substance abuse as a new indication for antipsychotic drug development?A George Awad
Journal of Psychiatry & Neuroscience : JPN|May 16, 2006
The rational use of medications in acute psychotic presentations -- the case for less is moreA George Awad
Expert Review of Pharmacoeconomics & Outcomes Research|August 21, 2015
'The patient': at the center of patient-reported outcomesA George Awad
Expert Review of Pharmacoeconomics & Outcomes Research|October 1, 2011
Quality-of-life assessment in schizophrenia: the unfulfilled promiseA George Awad
CNS Drugs|December 5, 2018
Revisiting the Concept of Subjective Tolerability to Antipsychotic Medications in Schizophrenia and its Clinical and Research Implications: 30 Years LaterA George Awad
Expert Review of Pharmacoeconomics & Outcomes Research|February 4, 2010
Subjective tolerability of antipsychotic medications and the emerging science of subjective tolerability disordersA George Awad
Acta Psychiatrica Scandinavica. Supplementum|May 10, 2005
Neuroleptic dysphoria 50 years laterA George Awad, Dieter Naber
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|June 17, 2004
Is neuroleptic dysphoria a variant of drug-induced extrapyramidal side effects?Lakshmi P Voruganti, A George Awad
Pageof 6